NIAID Banner Logo Image

TB Drugs in Development


Drug ClassSponsor and/or CompanyDrug NameAlt NameDrug StatusNotesAIDS#
Antibody, MonoclonalNational University, SingaporePascolizumabAnti-IL-4 AntibodyPhase 2Unknown 
Cell Wall Synthesis InhibitorUniversity Medical Center GroningenInvanz™ErtapenemPhase 2Completed 604819
Cell Wall Synthesis InhibitorOtsuka PharmOPC-167832 3,4-dihydrocarbostyril derivativePhase 1/2Recruiting 
Cell Wall Synthesis InhibitorJohns Hopkins University Merrem™Meropenem; SM-7338Phase 2Recruiting 007788
Cell Wall Synthesis InhibitorNational University, Singapore; Asubio PharmaFarom™FaropenemPhase 2Not yet recruiting 545326
Cell Wall Synthesis InhibitorEuropean and Developing Countries Clinical Trials Partnership (EDCTP); Michael Hoelscher, Ludwig-Maximilians, University of MunichBTZ043Benzothiazinone derivativePhase 1/2Not yet recruiting 538411
Cell Wall Synthesis InhibitorEuropean and Developing Countries Clinical Trials Partnership (EDCTP); SequellaSQ-109A novel 1,2-ethylene diaminePhase 2Completed 207396
Cell Wall Synthesis InhibitorGlobal Alliance for TB Drug DevelopmentTBA-354A nitroimidazolePhase 1Terminated 510946
Cell Wall Synthesis InhibitorGlobal Alliance for TB Drug DevelopmentTBA-7371An azaindolePhase 1Completed 555726
Cell Wall Synthesis InhibitorInnovative Medicines for Tuberculosis; Nearmedic Plus LLCMacozinoneMCZ; PBTZ-169Phase 1Recruiting 573761
CombinationNational Institute of Allergy and Infectious Diseases (NIAID)Imatinib and Isoniazid and Rifabutin Phase 2Not yet recruiting 
CombinationGlobal Alliance for TB Drug DevelopmentBPaLBedaquiline and Pretomanid and LinezolidFDA Approved (August 2019)  
CombinationGlobal Alliance for TB Drug DevelopmentBPaMZBedaquiline and Pretomanid and Moxifloxacin and PyrazinamidePhase 2/3Recruiting 
CombinationNational University Hospital, SingaporeCelecoxib and Rifampicin and Pyrazinamide Phase 1Completed 
CombinationNational University Hospital, SingaporeFaropenem and Amoxicillin (clavulanic acid) and Cefadroxil and Rifampicin Phase 2Not yet recruiting 
CombinationGlobal Alliance for TB Drug DevelopmentMidazolam and PA-824 Phase 1Completed 
CombinationThe HIV Netherlands Australia Thailand Research Collaboration Indinavir and Ritonavir Phase 1/2Completed 
CombinationUniversity Medical Center Groningen, NetherlandsIsoniazid and Co-TrimoxazoleIsoniazid and Trimethoprim and sulfamethoxazolePhase 3Completed 
CombinationPfizerLersivirine and RifabutinUK-453,061 and RifabutinPhase 1Completed 
Cytochrome bc1 Complex InhibitorQurient Co., Ltd.Telacebec Q203Phase 2Active, not recruiting 594207
DNA Methyltransferase InhibitorBaylor College of Medicine; Celgene CorporationVidaza™Azacitidine; AzacytidinePhase 2Not yet recruiting 000615
DNA Replication Inhibitor/TB Cell Division InhibitorNational Institute of Allergy and Infectious Diseases (NIAID); Parke-Davis; Kyorin Pharm; PfizerTequin™Gatifloxacin; GTFX; BMS-206584; AM-1155; CG 5501; PD-135432; GATPhase 1/2Completed 044913
DNA Replication Inhibitor/TB Cell Division InhibitorIUATLD, Inc; Daiichi Pharm; Sanofi-Aventis; Ortho-McneilLevaquin™; Tavanic™S-(-)-Ofloxacin; DR-3355; RWJ-25213; Cravit; L-Ofloxacin; Levofloxacin; LVXPhase 3Recruiting 002307
DNA Replication Inhibitor/TB Cell Division InhibitorNational Institute of Allergy and Infectious Diseases (NIAID); BayerFlagyl™Metronidazole; Bayer 5360; Clont; Danizol; Gineflavir; Metric 21; Trichazol; Trichopal; Trivazol; VagilenPhase 2Completed 007953
DNA Replication Inhibitor/TB Cell Division InhibitorGlobal Alliance for TB Drug Development; Bayer; Schering-PloughAvelox™Moxifloxacin; MXFX; BAY 12-8039; Actira; AveloxPhase 3Completed 070017
GyrB ATPase InhibitorSpero Therapeutics, LLCSPR720VXc-100, VXc-486; An ethyl urea benzimidazolePhase 1Recruiting 
Host-directed TherapyJohns Hopkins University Pravachol™PravastatinPhase 2Not Yet Recruiting 488445
Intracellular NO ReleaseGlobal Alliance for TB Drug Development; Pathogenesis Corp; ChironPretomanidPA-824New Drug Application (NDA) Submitted (March 2019)  007331
Leucyl-tRNA Synthetase (LeuRS) InhibitorGlaxoSmithKlineGSK3036656GSK070Phase 2Recruiting 599488
Mycolic acid Biosynthesis InhibitorWits Health Consortium (Pty) Ltd; Otsuka PharmDeltyba™Delamanid; OPC-67683Phase 3Not yet recruiting 182259
Protein Synthesis InhibitorMicuRx PharmaceuticalsMRX-4Prodrug of Contezolid (MRX-1)Phase 1Completed 
Protein Synthesis Inhibitor/TB Growth InhibitorLegoChem Biosciences, Inc.DelpazolidLCB01-0371Phase 2Recruiting 581214
Protein Synthesis Inhibitor/TB Growth InhibitorNational Institute of Allergy and Infectious Diseases (NIAID); AstraZenecaPosizolidAZD2563; AZD5847Development Discontinued  554767
Protein Synthesis Inhibitor/TB Growth InhibitorGlobal Alliance for TB Drug DevelopmentTBI-223Novel oxazolidinonePhase 1Active, not recruiting 592820
Protein Synthesis Inhibitor/TB Growth InhibitorNational University Hospital, Singapore Vibramycin™DoxycyclinePhase 2Completed 000242
Protein Synthesis Inhibitor/TB Growth InhibitorGlobal Alliance for TB Drug Development; Pharmacia & Upjohn, Inc.; PfizerZyvox™Linezolid; LZD; PNU-100766Phase 3Recruiting 070944
Protein Synthesis Inhibitor/TB Growth InhibitorEuropean and Developing Countries Clinical Trials Partnership (EDCTP); Pharmacia & Upjohn, Inc.; PfizerSutezolidPNU-100480; PF-02341272; OxazolidininonePhase 2Not yet recruiting 045415
Pyruvate-Ferredoxin Oxidoreductase InhibitorWeill Medical College of Cornell UniversityAlinia™ ; Nizonide™A nitazoxanidePhase 2Completed 057131
UnidentifiedScientific Center for Anti-infectious Drugs, KazakhstanFS-1Molecular iodine complex with bioorganic ligands, magnesium and lithium halogenidesPhase 3Active, not recruiting 

If using ChemDB information for publication or abstract presentation, please cite the website in addition to the original information source.    Database last updated: September 2019